



00270

PATENT TRADEMARK OFFICE

SEQUENCE LISTING

4

<110> Gevas, Philip
Grimes, Stephen
Karr, Stephen
Michaeli, Dov
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<140> US 09/700,329
<141> 2001-02-08

<150> PCT/US99/10751
<151> 1999-05-14

<150> 60/085,714
<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1
<211> 9
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu Glu
1 5

<210> 2
<211> 12
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 2

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys
1 5 10

<210> 3
<211> 7
<212> PRT
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys
1 5

<210> 4
<211> 7
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (7)..(7)
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp
1 5

<210> 5
<211> 12
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys
1 5 10

<210> 6
<211> 11
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Pro Cys
1 5 10

<210> 7
<211> 10
<212> PRT
<213> human gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Pro Cys
1 5 10

<210> 8
<211> 12
<212> PRT
<213> rat gastrin peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Pro Cys
1 5 10

<210> 9
<211> 15
<212> PRT
<213> human gastrin peptide

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Pro Cys
1 5 10 15

[Barcode]
00270
PATENT TRAUMANS OFFICE

Exhibit A

COPY

PATENT

Serial No. 09/270329 Doc. No. 11-14-6 Atty/Sec Mrs. J. L. H. Date 11-14-6
 Inventor J. Gervais et al. Client ACG.

Title Prevention and Treatment of Hyperglycemia

The following has been received in the U.S. Patent and Trademark Office on the date stamped hereon:

- 22 pp. Spec., 20 Claims, 1 pg. Abstract _____ pp. Amendment: OA dtd _____
- 3 pp. Declaration/Power of Attorney _____ pp. Response: OA dtd _____
- 1 pp. Verified Statement (Small Entry) _____ pp. Transmittal Letter _____
- 12 shts. Informal Drawings _____ Issue Fee _____
- 12 shts. Formal Drawings (Fig. 1-12) _____ Notice of Appeal & Fee _____
- 2 pp. Assignment _____ Check # 15703 for \$ 345.00
- 2 pp. Preliminary Amendment _____ 1 pg. Second Prel. Amend.
- pp. Extension of Time _____ 1 pg. Transmittal Letter
- pp. Information Disclosure Statement _____ 3 pg. Disc. List - 1 pg. Standard
- with PTO-1449 and _____ references _____ 3 pg. Disc. List - 1 pg. Standard

The Patent and Trademark Office is respectfully requested to place its stamp on this postal card and place it in the outgoing mail.

Express Mail w

DK99570329US

MEFS 09/700329

525 Rec'd PCT/PTO 14 NOV 2000

Respectfully,
HOWSON AND HOWSON

acg2usa.ST25

Copies
Exhibit B

SEQUENCE LISTING

COPY

<110> Gevas, Philip
Grimes, Stephen
Karr, Stephen
Michaeli, Dov
Watson, Susan

<120> Prevention and Treatment of Hypergastrinemia

<130> ACG2USA

<150> PCT/US99/10751
<151> 1999-05-14

<150> 60/085,714
<151> 1998-05-15

<160> 9

<170> PatentIn version 3.0

<210> 1
<211> 9
<212> PRT
<213> human

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 1

Glu Gly Pro Trp Leu Glu Glu Glu
1 5

<210> 2
<211> 12
<212> PRT
<213> human

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 2


00270
PATENT TRADEMARK OFFICE

acg2usa.ST25

Glu Leu Gly Pro Gln Gly Arg Pro Pro Pro Pro Cys
1 5 10

<210> 3
<211> 7
<212> PRT
<213> human or synthetic peptide

<400> 3

Ser Ser Pro Pro Pro Pro Cys
1 5

<210> 4
<211> 7
<212> PRT
<213> human or synthetic peptide

<220>
<221> MOD_RES
<222> (7)..(7)
<223> AMIDATION

<400> 4

Glu Ala Tyr Gly Trp Met Asp
1 5

<210> 5
<211> 12
<212> PRT
<213> human

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 5

Glu Gly Pro Trp Leu Glu Arg Pro Pro Pro Pro Cys
1 5 10

<210> 6
<211> 11
<212> PRT
<213> human

<220>

acg2usa.ST25

<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 6

Glu Gly Pro Trp Leu Arg Pro Pro Pro Cys
1 5 10

<210> 7
<211> 10
<212> PRT
<213> human

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 7

Glu Gly Pro Trp Arg Pro Pro Pro Cys
1 5 10

<210> 8
<211> 12
<212> PRT
<213> rat

C/
cont

<220>
<221> MOD_RES
<222> (1)..(1)
<223> pyroglutamic acid

<400> 8

Glu Arg Pro Pro Leu Glu Arg Pro Pro Pro Cys
1 5 10

<210> 9
<211> 15
<212> PRT
<213> human

<400> 9

Asp Pro Ser Lys Lys Gln Gly Pro Trp Leu Pro Pro Pro Cys
1 5 10 15